RESUMEN
The US Centers for Disease Control and Prevention recommends the initial use of rapid antigen influenza diagnostic test (RIDT) for the detection of influenza A (H1N1-09). Nasopharyngeal samples were tested from 246 patients for H1N1-09 using target-enriched multiplex polymerase chain reaction (TEM-PCR), of which 163 were additionally tested via RIDT. RIDTs had a sensitivity of 18.7% compared with TEM-PCR as the reference standard. Patients with false-negative RIDTs were withheld from 111 days of oseltamivir and 65 days of isolation. Patients negative for H1N1 via TEM-PCR had antiviral therapy immediately stopped, thereby evading 408 days of oseltamivir and 315 days of unnecessary isolation. This cost avoidance saved US$208,982.
Asunto(s)
Antivirales/economía , Gripe Humana/diagnóstico , Técnicas de Diagnóstico Molecular/métodos , Reacción en Cadena de la Polimerasa Multiplex/métodos , Nasofaringe/virología , Oseltamivir/economía , Antivirales/uso terapéutico , Costos de la Atención en Salud , Humanos , Gripe Humana/tratamiento farmacológico , Oseltamivir/uso terapéutico , Aislamiento de Pacientes/economía , Aislamiento de Pacientes/métodos , Estudios Retrospectivos , Resultado del Tratamiento , Estados UnidosRESUMEN
The prevalence of urinary tract infections in calves aged seven days to three months in three dairy cattle herds ranged from 0.5 to 1.6 per cent, with an average of 1.1 per cent. The mortality rate reached 16.1 per cent. The morbidity rate of the female calves was 1.4 per cent and that of the male calves 0.8 per cent. The bacteria isolated from urine, and from vaginal and preputial swabs were Escherichia coli (35 per cent), Corynebacterium renale (14 per cent), plasma coagulase-negative Staphylococcus species (12 per cent), Pseudomonas aeruginosa (12 per cent), Proteus species (12 per cent) and Arcanobacterium pyogenes (5 per cent). The affected calves had a significantly lower serum concentration of inorganic phosphorus (P < 0.01).
Asunto(s)
Enfermedades de los Bovinos/epidemiología , Infecciones Urinarias/veterinaria , Animales , Animales Recién Nacidos , Bovinos , Enfermedades de los Bovinos/microbiología , Femenino , Israel/epidemiología , Masculino , Prevalencia , Urinálisis/veterinaria , Infecciones Urinarias/epidemiología , Vagina/microbiologíaRESUMEN
BACKGROUND: Three women have been identified with an antibody to a "new" high-incidence antigen found on multiple cell lines. CASE REPORTS: The proposita, M.A.M., presented during her third pregnancy with an antibody reacting with all RBCs tested except her own. She delivered a thrombocytopenic infant with a 3+ DAT, but without symptoms of HDN. The second example, A.N., presented during her third pregnancy with an antibody reacting with all RBCs tested except her own and those of M.A.M. She delivered a slightly thrombocytopenic but severely anemic infant. The third example, F.K., a sister of A.N., has an antibody reacting with all RBCs tested except her own and those of M.A.M. and A.N. CONCLUSION: This "new" high-incidence antigen has been named MAM and assigned high-incidence antigen number 901016 by the International Society of Blood Transfusion. The corresponding antibody, anti-MAM, has been shown to cause HDN and has the potential to shorten RBC survival after the transfusion of incompatible RBC units, as determined by monocyte monolayer assay. Immunoblotting and flow cytometry show that this new antibody reacts with various WBC lines in addition to RBCs. This antibody also appears to react with platelets in some assays.